Drug interaction check: will itraconazole alter BI 1015550 levels?
NCT ID NCT03403439
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This completed Phase 1 trial tested whether taking the antifungal itraconazole changes how the body processes a single dose of the experimental drug BI 1015550 (Nerandomilast). Sixteen healthy men received the drug alone and then again while on a 12-day course of itraconazole. Researchers measured drug levels in the blood to see if there is a meaningful interaction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1015550 (Nerandomilast) and itraconazole
What this could lead to
If successful, this study will show whether itraconazole changes how the body absorbs BI 1015550, helping guide safe dosing in future trials.
What could go wrong
This is a very early, small study in only 16 healthy men, so results may not apply to patients or predict real-world effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.